Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05886764 · ClinicalTrials.gov registry record · NA

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

A NA study of Cancer and Malignant Neoplasm, sponsored by University of Chicago.

Recruiting
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT05886764: Recruiting NA study of Cancer and Malignant Neoplasm, sponsored by University of Chicago.

NCT05886764 is a NA study of Cancer and Malignant Neoplasm that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 180 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05886764, a NA study of Cancer and Malignant Neoplasm, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

This trial will study different outreach methods to assess impact on enrollment of underrepresented minorities (specifically African Americans) to early phase cancer clinical treatment trials. Both patients and providers (those seeing enrolled patients) will be enrolled and receive the study interventions or no intervention (control arm).

Interventions

  • OTHER Digital Intervention
  • OTHER Community Outreach

Study Locations (1)

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2023-10-23
Est. Completion 2027-07
Phase NA
University of Chicago

796 total trials

What NCT05886764 shows while recruiting

NCT05886764 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Digital Intervention is the first listed.

NCT05886764 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05886764 about?

NCT05886764 is a clinical study titled "Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials". This trial will study different outreach methods to assess impact on enrollment of underrepresented minorities (specifically African Americans) to early phase cancer clinical treatment trials. Both patients and providers (those seeing enrolled patients) will be enrolled and receive the study interve...

What is the current status of trial NCT05886764?

This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2023-10-23. Estimated completion is 2027-07.

What conditions does trial NCT05886764 study?

This clinical trial studies the following conditions: Cancer, Malignant Neoplasm, Malignancy.

What interventions are being tested in trial NCT05886764?

The interventions under investigation include: Digital Intervention (OTHER), Community Outreach (OTHER).

Who is sponsoring clinical trial NCT05886764?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05886764 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05886764's enrollment target sits among peer trials

180 247th of 615 higher than 369 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05886764, the US trial registry maintained by the National Library of Medicine. NCT05886764 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.